Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
End‐of‐treatment response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sustained virological response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · patients on HD with HCV infection
Standard interferon plus ribavirin may leads to higher treatment discontinuation compared with standard interferon alone (low certainty).
1 finding from 1 review
Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients on HD with HCV infection
Standard interferon showed no clear difference in death compared with placebo or control (low certainty).
1 finding from 1 review
Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection
Standard interferon showed no clear difference in relapse(recurrence after stopping intervention) compared with placebo or control (low certainty).
1 finding from 1 review
End‐of‐treatment response · patients on HD with HCV infection
Standard interferon probably leads to higher end‐of‐treatment response compared with placebo or control (moderate certainty).
1 finding from 1 review
Sustained virological response · patients on HD with HCV infection
Standard interferon showed no clear difference in sustained virological response 6 months after stopping treatment compared with placebo or control (moderate certainty).
1 finding from 1 review
Treatment discontinuation · patients on HD with HCV infection
Standard interferon showed no clear difference in treatment discontinuation compared with placebo or control (moderate certainty).
1 finding from 1 review
Adverse events · patients on HD with HCV infection
Standard interferon showed no clear difference in adverse events compared with placebo or control (moderate certainty).
1 finding from 1 review